Back Hepatitis C

Hepatitis C

AASLD 2017: Curing Hepatitis C Leads to Improved Quality of Life

People who were cured of hepatitis C with direct-acting antivirals had sustained improvements in their health-related quality of life, including both physical and mental health measures, according to study results presented at the AASLD Liver Meeting last week in Washington, DC.

alt

AASLD 2017: Mavyret Shows High Cure Rates for HCV Genotype 3 and Cirrhosis

Glecaprevir and pibrentasvir, the 2 drugs in the recently approved Mavyret coformulation, demonstrated high sustained response rates for chronic hepatitis C patients with HCV genotype 3 and for people with liver cirrhosis, according to a pair of reports presented at the 2017 AASLD Liver Meeting last week in Washington, DC.

alt

Does Drug Injection Equipment Other than Syringes Transmit Hepatitis C?

Sharing drug preparation paraphernalia may not significantly contribute to hepatitis C virus (HCV) transmission among people who inject drugs, according to a study recently published in the Journal of Infectious Diseases.

alt

AASLD 2017: Curing Hepatitis C with DAAs Reduces Liver Cancer Risk

People who achieved a sustained virological response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, according to study results presented at the 2017 AASLD Liver Meeting last week in Washington, DC.

alt

 

INHSU 2017: People Who Use Drugs Should Be Prioritized for Hepatitis C Treatment

People who use drugs should be given high priority for antiviral treatment as a way to eliminate hepatitis C as a public health concern, according to a statement issued at the 6th International Symposium on Hepatitis Care in Substance Users, held earlier this month in Jersey City.

alt

AASLD 2017: HCV Infections Are Rising Among HIV+ Gay Men In San Diego

Hepatitis C incidence is increasing among gay and bisexual men living with HIV in San Diego, according to the largest analysis of its kind done in the United States. Study results were presented last week at the 2017 AASLD Liver Meeting in Washington, DC.

alt

Janssen Discontinues Hepatitis C Drug Development Program

Janssen Sciences announced last week that it will stop further development of its experimental hepatitis regimen containing AL-335, odalasvir, and simeprevir, as the market is saturated with effective therapies. It will instead focus on hepatitis B, which is seldom cured with existing antiviral medications.

alt

Merck Discontinues Development of Experimental Hepatitis C Drugs

Late last month Merck announced that it was halting further development of 2 investigational hepatitis C therapies. The first is a 3-drug coformulation containing the HCV protease inhibitor grazoprevir, the NS5A inhibitor ruzasvir, and the HCV polymerase inhibitor uprifosbuvir. The second is a 2-drug combo containing ruzasvir and uprifosbuvir.

alt

Experts Question Cochrane Review of Hepatitis C DAA Treatment

A systematic review of hepatitis C direct-acting antiviral (DAA) studies published by the Cochrane Collaboration has been strongly criticized by doctors and advocates for its conclusion that there is no evidence that the expensive drugs prolong life or reduce liver-related disease in people who achieve a sustained virological response to treatment -- a cure, in current understanding.

alt